SGEN - Sector: Healthcare---Industry: Biotechnology & Drugs

[kslifka]

Love the set up with this one for tomorrow and possibly beyond.  Had a gap because of deal with Genentec.

G-breakout.   As of writing this writing trading at 6.96 with increasing volume

[la-onda]

applauds 

1)
Seattle Genetics "buy," target price raised - update
Tuesday, December 12, 2006 12:46:38 PM ET
Banc of America
NEW YORK, December 12 (newratings.com) - Analyst David Witzke of Banc of America Securities reiterates his "buy" rating on Seattle Genetics (SGEN.NAS). The target price has been raised from $6 to $9.
In a research note published this morning, the analyst mentions that following the company's recent release of positive updated data from the Phase I trial of SGN-40 in NHL, the estimate for the probability of success of the trial has been raised from 25% to 40%. The analyst expects SGN-40 to emerge as Seattle Genetics' leading commercial candidate for the treatment of NHL. There also is potential for the use of SGN-40 in CLL and multiple myeloma, Banc of America Securities adds.

2)
Seattle Genetics upgraded to "outperform" - update
Wednesday, January 10, 2007 2:53:45 AM ET
RBC Capital Markets
NEW YORK, January 10 (newratings.com) - Analyst Jason Kantor of RBC Capital Markets upgrades Seattle Genetics Inc (SGEN.NAS) from "sector perform" to "outperform," while raising his estimates for the company. The target price has been raised from $6 to $9.
In a research note published yesterday, the analyst mentions that the partnership with Genentech for SGN-40 significantly reduces Seattle Genetics' financial risk. The deal also potentially widens and accelerates SGN-40's development and frees resources for Seattle Genetics to advance other proprietary drug candidates, the analyst says. Seattle Genetics is likely to receive $20 million in committed research funding over two years and accelerating double-digit royalties on potential sales in the future, RBC Capital Markets adds.

3)
Seattle Genetics "buy," target price raised
Tuesday, January 09, 2007 12:35:34 PM ET
Needham & Co
NEW YORK, January 9 (newratings.com) - Analysts at Needham & Co reiterate their "buy" rating on Seattle Genetics Inc (SGEN.NAS). The target price has been raised from $8 to $10.

you are already invested (now @ 6.87$)  ?
cheers
O.

[kslifka]

As expected moved above the G-breakout.  Maybe a runaway Gap

[kslifka]

Bounced off G-breakout.  Recovery in progress...hopefully to continue

[setravis]

Nice pick kslifka...Applaud 
"It's a great company with an excellent management team."

Seattle Genetics grabs investor notice,shares soar !
shares closed up 11 percent to a multiyear high on Friday, a day after a 15 percent jump, with analysts saying the biotechnology company was undervalued and possibly a target for big drugmakers eager for new products.
Analysts also said Seattle Genetics had executives on a marketing trip in New York this week that appears to have helped spark investor attention.

Seattle last month signed an $860 million partnership deal with Genentech Inc.
for its leading experimental cancer drug in development.
The deal with the world's leading cancer drug company validated Seattle Genetics' technology...

"At the levels it was trading prior to (this week's) run-up, it was really undervalued. It was trading in the $6 range and that's hugely undervalued."

52wk Range: 3.81 - 7.80
Volume: 7,783,055
Avg Vol (3m): 5,363,260

Technicals
Record Price High
Percentage Gainer

Last Price Quote is:
30.20%above 13-day MA
47.49%above 50-day MA
RS Rating: 98 

Fundamentals
Earnings Expected on Feb 6

Key Data:
Market Cap (M): $221.91 
P/E Ratio: NA 
PEG Ratio: N/A 
Next Earnings: 02/06/2007
Last Analyst Rating: Outperform

[kslifka]

Thanks Setravis...but unfortunately I sold a couple weeks ago

[Ares]

Setting alert at 9.52 (52 Week High)

[Ares]

Will SGEN get some blocks today?

[basonista]

Could be setting up to run some more.

[setravis]

TO RECEIVE $12M MILESTONE PAYMENT FROM PH IIB TRIAL: Seattle Genetics, Inc.
(SGEN) has initiated a phase IIb clinical trial of SGN-40 in combination with Rituxan(R) (rituximab)
plus chemotherapy for patients with relapsed or refractory diffuse large B-cell lymphoma
(DLBCL). Under the terms of the company's collaboration agreement with Genentech, Inc.
(DNA), Seattle Genetics will receive a $12 million milestone payment for initiating the study. The
phase IIb, randomized, double-blind, placebo-controlled clinical trial is expected to enroll approximately
200 relapsed or refractory DLBCL patients at more than 60 medical centers worldwide.
The primary endpoint of the study is complete response rate. Additional endpoints include
safety, tolerability, failure-free and overall survival.

[setravis]

Seattle Genetics and Millennium Announce Positive Top-Line Results...

BOTHELL, Wash. & CAMBRIDGE, Mass., Sep 27, 2010 (BUSINESS WIRE) -- ---BLA Submission Planned in First Half of 2011-

---Seattle Genetics to Host Conference Call and Webcast Today at 8:30 a.m. ET-

Seattle Genetics, Inc. (SGEN) and Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited , today announced positive top-line results from the pivotal trial of single-agent brentuximab vedotin (SGN-35), an antibody-drug conjugate (ADC) targeted to CD30. The trial was conducted in 102 relapsed or refractory Hodgkin lymphoma (HL) patients.

Seventy-five percent of patients in the pivotal trial achieved an objective response as assessed by an independent central review, the primary endpoint of the trial. The median duration of response was greater than six months. The safety profile of brentuximab vedotin in this trial was generally consistent with prior clinical trial experience. A more complete data set will be presented at an upcoming scientific meeting.

"We are extremely excited with the top-line results, as they move us one step closer to our goal of bringing brentuximab vedotin to patients with relapsed or refractory Hodgkin lymphoma," said Clay B. Siegall, Ph.D., President and Chief Executive Officer of Seattle Genetics. "We are positioned for a Biologics License Application (BLA) submission to the U.S. Food and Drug Administration (FDA) in the first half of 2011. In addition, we plan to report top-line data from our phase II trial of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma (ALCL) within the next few weeks."

"The lack of adequate therapies for the treatment of relapsed and refractory Hodgkin lymphoma represents a substantial unmet medical need worldwide, with almost a third of the 30,000 newly diagnosed patients relapsing or becoming refractory to front-line therapy annually," said Nancy Simonian, M.D., Chief Medical Officer of Millennium. "These data have the potential to provide an important advance in therapy for Hodgkin lymphoma. We intend to discuss these results with European regulators to support our goal of submitting a Marketing Authorization Application to the European Medicines Agency (EMA) in 2011."

Pivotal Trial Design

The single-arm pivotal trial assessed efficacy and safety of single-agent brentuximab vedotin in relapsed or refractory, post-autologous stem cell transplant (ASCT) HL patients. Patients received 1.8 milligrams per kilogram of brentuximab vedotin every three weeks for up to 16 total doses. The primary endpoint of the trial was objective response rate as assessed by an independent review facility. Response assessments were based on the rigorous and internationally established Revised Response Criteria for Malignant Lymphoma (Cheson, 2007). Secondary endpoints included complete response rate, duration of response, progression-free survival, overall survival and tolerability. The trial was conducted under a Special Protocol Assessment (SPA) with the FDA and was discussed with the EMA during the process of obtaining EU Centralized Scientific Advice on the brentuximab vedotin development program. Brentuximab vedotin has been granted orphan drug designation by the FDA and EMA for the treatment of HL and ALCL and has been granted fast track designation by the FDA for HL.

About Brentuximab Vedotin

Brentuximab vedotin is an ADC comprising an anti-CD30 monoclonal antibody attached by an enzyme cleavable linker to a potent, synthetic drug payload, monomethyl auristatin E (MMAE) utilizing Seattle Genetics' proprietary technology. The ADC employs a novel linker system that is designed to be stable in the bloodstream but to release MMAE upon internalization into CD30-expressing tumor cells. This approach is intended to spare non-targeted cells and thus may help minimize the potential toxic effects of traditional chemotherapy while allowing for the selective targeting of CD30-expressing cancer cells, thus potentially enhancing the antitumor activity.

In addition to the pivotal HL trial, Seattle Genetics and Millennium are conducting a phase II trial for relapsed and refractory systemic ALCL, a phase III clinical trial (the AETHERA trial) for patients at high risk of residual HL following autologous stem cell transplant, a phase II retreatment trial for relapsed patients who previously responded to brentuximab vedotin, and a phase I combination trial for front-line treatment of HL.

About Hodgkin Lymphoma

Lymphoma is a general term for a group of cancers that originate in the lymphatic system. There are two major categories of lymphoma: Hodgkin lymphoma and non-Hodgkin lymphoma. Hodgkin lymphoma is distinguished from other types of lymphoma by the presence of one characteristic type of cell, known as the Reed-Sternberg cell. A defining attribute of the Reed-Sternberg cell is its expression of the CD30 antigen.

According to the American Cancer Society, approximately 8,500 cases of Hodgkin lymphoma will be diagnosed in the United States during 2010 and more than 1,300 will die from the disease. Globally, there are more than 30,000 cases of Hodgkin lymphoma diagnosed each year. Although front-line combination chemotherapy can result in durable response rates, up to 30 percent of these patients relapse or are refractory to front-line treatment and have few therapeutic options beyond ASCT.

About the Seattle Genetics/Millennium Collaboration

Seattle Genetics and Millennium are jointly developing brentuximab vedotin. Under the terms of the collaboration agreement, Seattle Genetics has U.S. and Canadian commercialization rights and the Takeda Group has rights to commercialize brentuximab vedotin in the rest of the world. Seattle Genetics and the Takeda Group are funding joint development costs for brentuximab vedotin on a 50:50 basis, except in Japan where the Takeda Group will be solely responsible for development costs.

Conference Call Details

Seattle Genetics' management will host a conference call and webcast to discuss this announcement. The event will be held today at 5:30 a.m. Pacific Time (PT); 8:30 a.m. Eastern Time (ET). The live event will be available from Seattle Genetics' website at http://www.seattlegenetics.com , under the Investors and News section, or by calling (877) 941-8631 (domestic) or (480) 629-9819 (international). The access code is 4369251. A replay of the discussion will be available beginning at approximately 7:00 a.m. PT today from Seattle Genetics' website or by calling (800) 406-7325 (domestic) or (303) 590-3030 (international), using access code 4369251. The telephone replay will be available until 5:00 p.m. PT on Friday, October 1, 2010.

About Seattle Genetics

Seattle Genetics is a clinical-stage biotechnology company focused on the development and commercialization of monoclonal antibody-based therapies for the treatment of cancer and autoimmune disease. The company's lead product candidate, brentuximab vedotin, is being evaluated in a variety of lymphoma treatment settings including the relapsed and refractory Hodgkin lymphoma indication for which top-line pivotal data have been reported. In addition, Seattle Genetics has four other clinical-stage programs: SGN-75, ASG-5ME, dacetuzumab (SGN-40) and SGN-70. Seattle Genetics has collaborations for its ADC technology with a number of leading biotechnology and pharmaceutical companies, including Bayer, Celldex Therapeutics, Daiichi Sankyo, Genentech, GlaxoSmithKline, MedImmune, a subsidiary of AstraZeneca, Millennium: The Takeda Oncology Company and Progenics, as well as ADC co-development agreements with Agensys, an affiliate of Astellas, and Genmab. More information can be found at www.seattlegenetics.com .

About Millennium

Millennium: The Takeda Oncology Company, a leading biopharmaceutical company based in Cambridge, Mass., markets a first-in-class proteasome inhibitor, and has a robust clinical development pipeline of product candidates. Millennium Pharmaceuticals, Inc. was acquired by Takeda Pharmaceutical Company Ltd. in May, 2008. The Company's research, development and commercialization activities are focused in oncology. Additional information about Millennium is available through its website, www.millennium.com .

For Seattle Genetics: Certain of the statements made in this press release are forward looking, such as those, among others, relating to the potential therapeutic benefit of brentuximab vedotin and plans for filing for regulatory approval with and obtaining regulatory approval from the FDA and the EMA. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include that the safety and/or efficacy results of the pivotal trial in relapsed or refractory Hodgkin lymphoma will not be sufficient to gain marketing approval in the United States or any other country, that we will be required to amend our submission for marketing approval or that such submission will be refused. In addition, our regulatory plans may change as a result of consultation with the FDA or EMA. More information about the risks and uncertainties faced by Seattle Genetics is contained in the company's 10-Q for the quarter ended June 30, 2010 filed with the Securities and Exchange Commission. Seattle Genetics disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

SOURCE: Seattle Genetics, Inc.


Seattle Genetics, Inc.
Peggy Pinkston, 425-527-4160
[email protected]
or
Millennium
Lauren Musto, 617-551-7848
[email protected]

[setravis]

NEW YORK (Dow Jones)--Seattle Genetics Inc. (SGEN) said its novel blood cancer treatment, which attacks cancerous cells but ignores healthy ones, shrank tumors in three-quarters of patients with Hodgkin lymphoma, according to a study released Monday.
The results easily surpassed expectations and sent shares of Seattle Genetics up as much as 24% to a new 52-week high.

52wk Range: 8.26 - 15.08
Volume: 10,598,033
Avg Vol (3m): 664,578

Technicals
Record Price High
Close Above the 50-day MA
Close Above the 13-day MA
Most Actives
Record Price Break Out
Gap Up
Percentage Gainer

Last Price Quote is:
18.73%above 13-day MA
17.99%above 50-day MA
RS Rating: 74 

[setravis]

SGEN  Seattle Genetics Reports Preliminary Data from Phase... 

SEATTLE, Oct 11, 2010 (BUSINESS WIRE) -- Seattle Genetics, Inc. (SGEN) today reported data from a phase I clinical trial of SGN-75 in patients with non-Hodgkin lymphoma or renal cell carcinoma (RCC). Preliminary results demonstrate tolerability and antitumor activity, including two objective responses in the first 16 patients treated. Dose-escalation is continuing. SGN-75 is an antibody-drug conjugate (ADC) targeted to CD70. The data were presented at the 35th European Society for Medical Oncology (ESMO) Congress being held in Milan, Italy.

"These preliminary data are encouraging, and show initial evidence of antitumor activity with SGN-75 in patients with relapsed/refractory non-Hodgkin lymphoma or metastatic RCC," said Jonathan Drachman, M.D., Senior Vice President, Research and Translational Medicine of Seattle Genetics. "We are continuing to dose escalate in this trial to further assess the safety and activity of SGN-75, as well as to establish the optimal dosing regimen for future clinical trials."

Data were reported from 16 patients in the open-label phase I clinical trial, including seven with non-Hodgkin lymphoma and nine with RCC. Cohorts of patients received SGN-75 either every three weeks at doses ranging from 0.3 to 2.0 milligrams per kilogram (mg/kg) or on a weekly basis at a dose of 0.3 mg/kg. Enrolled patients in each indication had received a median of three prior systemic therapies.

Best clinical response among non-Hodgkin lymphoma patients included one patient with a complete remission, four patients with stable disease, one patient with progressive disease and one patient who was not evaluable. Best clinical response among RCC patients included one patient with a partial response, three patients with stable disease and five patients with progressive disease. The most common adverse events were fatigue, nausea and peripheral edema (swelling). A maximum tolerated dose has not been established with either dosing schedule and dose escalation continues. (Abstract #532P)

The single-agent phase I study of SGN-75 was initiated in November 2009 and is designed to enroll up to approximately 80 patients at multiple centers in the United States. The trial is evaluating the safety, tolerability, pharmacokinetic profile and antitumor activity of SGN-75. Patients enrolled in the trial must have received at least one prior therapy and have confirmed CD70 expression.

SGN-75 is an ADC comprising an anti-CD70 antibody attached to a potent, synthetic cell-killing agent, monomethyl auristatin F (MMAF), using Seattle Genetics' proprietary technology. The ADC is designed to be stable in the bloodstream, and to release its cell-killing agent upon internalization into CD70-expressing tumor cells. This approach is intended to spare non-targeted cells and thus reduce many of the toxic effects of traditional chemotherapy while enhancing the antitumor activity.

About Non-Hodgkin Lymphoma

Non-Hodgkin lymphoma represents a diverse group of cancers that develop in the lymphatic system and are characterized by uncontrolled growth and accumulation of abnormal lymphocytes. Lymphocytes are white blood cells that are responsible for defending the body against infection. The most common forms of non-Hodgkin lymphoma are follicular and diffuse large B-cell lymphoma. According to the American Cancer Society, more than 65,000 cases of non-Hodgkin lymphoma are expected to be diagnosed in the United States during 2010 and more than 20,000 patients will die from the disease.

About Renal Cell Carcinoma

Renal cell carcinoma (RCC) forms in the kidney, which filters and cleans the blood. Metastatic RCC occurs when the cancer has spread to other parts of the body. RCC is the most common type of kidney cancer in adults, representing approximately 90 percent of cases. The American Cancer Society estimates that there will be more than 58,000 new cases of kidney cancer in the United States during 2010, and approximately 13,000 people will die from the disease.

About Seattle Genetics

Seattle Genetics is a clinical-stage biotechnology company focused on the development and commercialization of monoclonal antibody-based therapies for the treatment of cancer and autoimmune disease. The company's lead product candidate, brentuximab vedotin, is being evaluated in a variety of lymphoma treatment settings including the relapsed and refractory Hodgkin lymphoma indication for which top-line pivotal data have been reported. Brentuximab vedotin is being developed in collaboration with Millennium: The Takeda Oncology Company. In addition, Seattle Genetics has four other clinical-stage programs: SGN-75, ASG-5ME, dacetuzumab (SGN-40) and SGN-70. Seattle Genetics has collaborations for its ADC technology with a number of leading biotechnology and pharmaceutical companies, including Bayer, Celldex Therapeutics, Daiichi Sankyo, Genentech, GlaxoSmithKline, Millennium: The Takeda Oncology Company and Progenics, as well as ADC co-development agreements with Agensys, an affiliate of Astellas, and Genmab. More information can be found at www.seattlegenetics.com .

Certain of the statements made in this press release are forward looking, such as those, among others, relating to the therapeutic potential and continuation of the ongoing phase I clinical trial of SGN-75. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include risks related to adverse medical events or inconclusive clinical trial results in the ongoing phase I clinical trial, including the inability to show that SGN-75 is effective or to show sufficient safety in such clinical trials, and risks related to Seattle Genetics' ability to recruit and enroll a sufficient number of patients to participate in such clinical trials. More information about these and other risks and uncertainties faced by Seattle Genetics is contained under the heading "Risk Factors" in the company's quarterly report on Form 10-Q for the quarter ended June 30, 2010 filed with the Securities and Exchange Commission. Seattle Genetics disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

SOURCE: Seattle Genetics, Inc.


Seattle Genetics, Inc.
Peggy Pinkston, 425-527-4160
[email protected]

[setravis]

This Drugmaker Stands on a Platform Above the Rest...

antibody-drug conjugate technology; a drug is attached to an antibody that targets the drug to the right cells.

The most obvious application is in cancer, where the chemotherapy can be specifically targeted to tumor cells. In addition to potentially making the chemotherapy work better, the targeted antibody can also lower side effects since the chemotherapy isn't racing around the body attacking everything it sees willy-nilly. Recently presented data on ImmunoGen's most advanced compound, T-DM1, which Roche is developing, seem to support this: 66% of patients taking a combination of Roche's Herceptin and Sanofi's Taxotere lost their hair, compared to just 1.5% of patients taking T-DM1.

It's pretty clear that targeted antibodies are the wave of the future. Big drugmakers are going to turn their antibody drug candidates into potent killing machines, but it'll be the technology developers like ImmunoGen and Seattle Genetics that will be raking in the dough


Day's Range: 16.99 - 17.74
52wk Range: 8.26 - 18.05
Volume: 1,375,424
Avg Vol (3m): 1,123,480

Technicals
Last Price Quote is:
9.78%above 13-day MA
26.35%above 50-day MA
RS Rating: 91 

[setravis]

Seattle Genetics Earnings Conference Call (Q3 2010)

Seattle Genetics Earnings Conference Call (Q3 2010)
Scheduled to start Mon, Nov 1, 2010, 5:00 pm Eastern


Check back at the scheduled start time for
the audio link to appear in this spot.
Add This Event To Your Yahoo! Calendar

http://biz.yahoo.com/cc/4/117324.html

After the event has finished, the audio will be available
from this page until Wed, Nov 2, 2011


About Seattle Genetics (NasdaqGM:SGEN)
Seattle Genetics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing monoclonal antibody-based therapies for the treatment of cancer and autoimmune diseases. Its lead product, SGN-35, is in pivotal trial for patients with relapsed or refractory hodgkin lymphoma. The company's other product candidates in various stages of clinical trials include dacetuzumab (SGN-40), a humanized anti-CD40 antibody; lintuzumab (SGN-33), a humanized anti-CD33 antibody; SGN-70, a humanized anti-CD70 antibody for the treatment of autoimmune diseases; SGN-75, which is in Phase I clinical trials for metastatic renal cell carcinoma and non-Hodgkin lymphoma; ASG-5ME, a preclinical antibody-drug conjugate product candidate for the treatment of solid tumors; and SGN-19A, a preclinical antibody-drug conjugate product candidate for the treatment of hematologic malignancies. It has collaborations with Bayer Pharmaceuticals Corporation; Celldex Therapeutics, Inc.; Daiichi Sankyo Co., Ltd.; Genentech; GlaxoSmithKline LLC; MedImmune, Inc.; Millennium; and PSMA Development Company LLC. The company also has an antibody-drug conjugates co-development agreement with Agensys, Inc. The company was founded in 1997 and is headquartered in Bothell, Washington.